Monday , May 10 2021

The first human clinical trial of HIV Gammora offers potential treatment



An Israeli biotechnology company specializing in HIV and cancer treatment finally released the results of its first clinical study on HIV-drug Gammora and news brings renewed hope to many affected by this devastating retrovirus. It was found that it eliminates the new drug until 99% HIV virus inside four weeks treatment.

Integration causes apoptosis

The company is called Zion Medical, and Gammora is an innovative treatment consisting of a synthetic peptide compound derived from HIV-derived integrase. Integrations are enzymes produced retroviruses such as HIV that allow their genetic material to be integrated into the DNA of the infected cell.

Using this procedure, Gammora stimulates the integration of many fragments of HIV DNA into the genomic DNA of the host cell. This then basically triggers the apoptosis of the infected cell or self-reflection.

"These first clinical results were beyond our expectation and promise to find a cure for the disease that was discovered 35 years, "Said Dr. Esmira Naftali, Zion Medical Development Manager." Given the limited nature of this study, we are excited to demonstrate the efficacy of our drug in Phase 2b with more participants over a longer period of time. "

If this phase proved to be equally successful, its effects would literally change life. Today's common commercially available retrovirus treatment for HIV works by suppressing the spread of the virus but does not offer a cure for infection.

HIV patients can only hope that they will have a better life than a real rest. Zion Medical's pioneering, however, has the potential to destroy all cells carrying a viral HIV genome that actually treats infected patients.

Zion Medical Phase 1 / 2a Gammora Human Clinical Study found that most patients demonstrated a significant decrease in viral load to 90% from baseline during first four weeks. In part II of the study, Gammora was furthermore combined with other retrovirus treatments, which led to patients being able to 99% reduction of viral load compared to baseline values four weeks.

In addition, in the full range 10 weeks Tests found that Gammora is safe and well tolerated. In fact, no undesirable effects have been reported.

It increases the number of CD4 cells

In addition, Gammora was found to increase the number of CD4 cell patients – up to 97% from the baseline. CD4 cells, also referred to as T cells or T helper cells, are cells that kill the HIV virus. These are white blood cells that play a key role in the human immune system, the body's natural defenses against pathogens, infections and diseases.

As HIV infection progresses, CD4 cells decrease significantly. A person will be diagnosed with AIDS when their number falls below 200 and then taken into account with a high risk of serious illness. For reference, the normal range of healthy individuals for CD4 cells is approximately 500-1,500.

Zion Medical claims that Gammora "is designed to kill HIV-infected cells without harming uninfected cells." His success would change the course of the HIV virus forever.


Source link